Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.

@article{Beasley2019ControlledTO,
  title={Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.},
  author={R. Beasley and M. Holliday and H. Reddel and I. Braithwaite and S. Ebmeier and R. Hancox and T. Harrison and C. Houghton and K. Oldfield and A. Papi and I. Pavord and Mathew Williams and M. Weatherall},
  journal={The New England journal of medicine},
  year={2019},
  volume={380 21},
  pages={
          2020-2030
        }
}
BACKGROUND In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. The availability of data from clinical trials designed to better reflect clinical practice would be beneficial. METHODS We conducted a 52-week, randomized, open-label, parallel-group, controlled… Expand
Efficacy and safety of as-needed budesonide-formoterol in adolescents with mild asthma.
TLDR
In adolescents with mild asthma, as- needed BUD-FORM was superior to as-needed terbutaline for severe exacerbation reduction, with similar efficacy to BUD maintenance. Expand
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
TLDR
This post-hoc analysis of the SYmbicort Given as needed in Mild Asthma (SYGMA) 1 study investigated the short-term risk of severe exacerbations after a single day with various levels of reliever use. Expand
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial
TLDR
Budesonide-formoterol used as needed for symptom relief was more effective at preventing severe exacerbations than maintenance low-dose budesonide plus as-needed terbutaline, and support the 2019 Global Initiative for Asthma recommendation. Expand
Controlled trial of budesonide-formoterol as needed for mild asthma: Discussions from @respandsleepjc (#rsjc)
TLDR
This trial was undertaken with the intention of increasing external validity and assessing for the effectiveness of shortacting b2-agonist therapy on an as needed basis in a broader patient setting. Expand
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
TLDR
Budesonide-formoterol anti-inflammatory reliever therapy is generally well-tolerated in patients with mild asthma and has a safety profile similar to that of daily budesonide. Expand
The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.
TLDR
From a UK healthcare payer perspective, as-needed budesonide/formoterol is a cost-effective option for the treatment of mild asthma versus regular ICS. Expand
As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?
TLDR
There is insufficient evidence for the systematic recommendation of as-needed ICS-LABA instead of SABA on request for GINA step 1 or as a replacement for chronic ICS in Gina step 2, and ignoring the clinical histological benefits of chronic inhaled corticosteroids. Expand
Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study
TLDR
Results indicate the real-world effectiveness of budesonide/formoterol anti-inflammatory reliever and maintenance therapy is better than fixed-dose fluticasone/salmeterol plus as-needed SABA. Expand
Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma
TLDR
These post hoc analyses of NovelSTART provide the first evidence that the exacerbation risk reduction with budesonide–formoterol reliever Therapy versus salbutamol reliever therapy is similar in adults with intermittent and mild persistent asthma. Expand
Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
TLDR
In mild asthma, the timing of the ICS dose, when self-titrated through the vehicle of β2-agonist reliever use, is more important than total ICS doses in reducing severe exacerbation risk, when associated with greater overall as-neededβ2-agonists use. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
TLDR
In patients with mild asthma, as‐needed budesonide–formoterol provided superior asthma‐symptom control to as‐ needed terbutaline, assessed according to electronically recorded weeks with well‐controlled asthma, but was inferior to budesonid maintenance therapy. Expand
As‐Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
TLDR
In patients with mild asthma, budesonide–formoterol used as needed was noninferior to twice‐daily budesonides maintenance therapy with respect to the rate of severe asthma exacerbations during 52 weeks of treatment but was inferior in controlling symptoms. Expand
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.
TLDR
In patients with mild asthma, the symptom-driven use of inhaled beclomethasone and albuterol in a single inhaler is as effective as regular use of asthma medication and is associated with a lower 6-month cumulative dose of the inhaled corticosteroid. Expand
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma.
TLDR
High-dose budesonide/formoterol was effective and well tolerated for the treatment of acute asthma, with rapid onset of efficacy and a safety profile over 3h similar to high-dose salbutamol. Expand
Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.
TLDR
This trial investigated whether the SMART regimen would reduce the risk of overuse of β agonist, reduce the likelihood of patients to seek medical review when such episodes occurred, and if any reduction in severe asthma exacerbations would be at the cost of a higher burden of systemic corticosteroid. Expand
Formoterol Turbuhaler as reliever medication in patients with acute asthma
TLDR
In this study of patients presenting at emergency depts with acute asthma, formoterol Turbuhaler was well tolerated and, as rescue therapy, had an efficacy that was not different from that of salbutamol pressurised metered-dose inhaler with spacer 1,600 µg in the number of patients studied. Expand
Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations
TLDR
In this trial involving adults and adolescents with asthma, a personalized self‐management plan that included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate resulted in fewer severe asthma exacerbations than a plan in which the dose was not increased. Expand
Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma?
TLDR
It is proposed that randomized controlled trials investigating different combination ICS/β-agonist inhaler products prescribed according to this regimen in intermittent and mild asthma are an important priority. Expand
The paradoxes of asthma management: time for a new approach?
TLDR
It is proposed that SABA reliever monotherapy should be replaced by a combination of inhaled corticosteroid and formoterol, or similar rapid-onset bronchodilator, as reliever therapy for patients at GINA steps 1 or 2, to ensure early and more regular administration of a controller medication. Expand
Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis
TLDR
This study identified and analyzed data from published trials of patients with persistent asthma in which researchers compared the use of SMART versus conventional therapy with ICS with or without LABA as controller therapy and SABA as rescue therapy in patients aged ≥5 years. Expand
...
1
2
3
...